MKC-963 is an orally active and potent inhibitor targeting platelet aggregation-related pathways. MKC-963 exerts antithrombotic activity by inhibiting platelet aggregation, and can also induce autoinduction, i.e., upregulating the mRNA expression and activity of CYP3A4 enzyme to accelerate its own metabolism in vivo. MKC-963 is promising for research of platelet aggregation-related diseases (e.g., thrombosis)[1].
Molekulargewicht:
331.45
CAS Nummer:
[149549-14-4]
Formel:
C22H25N3
Target-Kategorie:
Platelet-activating Factor Receptor (PAFR)
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
